## PFE: Pfizer Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Precision Trading with Pfizer Inc. (PFE) Risk Zones**
- Source: Stock Traders Daily | 20251228T193200 | Neutral | Relevance: 100%
- This article provides a detailed analysis of Pfizer Inc. (PFE) stock, highlighting a neutral sentiment across all time horizons and an exceptional 26.6:1 risk-reward setup. It outlines specific institutional trading strategies, including long, breakout, and short positions, with defined entry zones, targets, and stop losses. The analysis emphasizes AI-generated real-time signals and multi-timeframe signal analysis to optimize trading decisions and manage risk.

**2. Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts**
- Source: ts2.tech | 20251227T204559 | Neutral | Relevance: 100%
- Pfizer Inc. (PFE) stock is holding steady in the mid-$20s as 2025 concludes, with investors considering the conflicting realities of near-term revenue pressures from fading COVID-era sales and patent expirations against the potential for long-term growth from its oncology pipeline and new categories like obesity. The company's 2026 guidance, which includes lower-than-expected EPS, and its strong dividend yield, are central to investor sentiment while the market awaits clearer growth visibility. Significant pipeline milestones, particularly in oncology, are seen as key to replacing declining legacy revenues.

**3. Vontobel Holding Ltd. Buys 95,393 Shares of Pfizer Inc. $PFE**
- Source: MarketBeat | 20251225T111731 | Neutral | Relevance: 100%
- Vontobel Holding Ltd. increased its stake in Pfizer Inc. by 13.0% during the third quarter, acquiring an additional 95,393 shares to own a total of 831,628 shares valued at approximately $21.19 million. Despite this investment, Pfizer faces near-term challenges including 2025 EPS guidance slightly below consensus and a safety review due to a patient death in a hemophilia trial. The company recently declared a quarterly dividend of $0.43, representing an annualized yield of around 6.9%.

**4. Pfizer Inc. $PFE Shares Sold by Meyer Handelman Co.**
- Source: MarketBeat | 20251227T124124 | Neutral | Relevance: 100%
- Meyer Handelman Co. reduced its stake in Pfizer Inc. (NYSE:PFE) by 3.3% in the third quarter, selling 42,830 shares and retaining 1,237,617 shares valued at $31,534,000. Pfizer recently declared a quarterly dividend of $0.43 per share, representing an annualized $1.72 dividend and a 6.9% yield. The biopharmaceutical company also reported quarterly EPS of $0.87, surpassing estimates by $0.08, on revenue of $16.65 billion, and set its FY2025 EPS guidance between $3.00 and $3.15.

**5. Litman Gregory Wealth Management LLC Makes New Investment in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251227T115008 | Somewhat-Bullish | Relevance: 100%
- Litman Gregory Wealth Management LLC has acquired a new stake of 44,398 shares in Pfizer Inc. (NYSE:PFE) during the third quarter, valued at approximately $1.131 million. Other institutional investors have also adjusted their holdings in Pfizer, which recently beat Q3 EPS estimates with $0.87 reported against an expected $0.79. Pfizer also declared a quarterly dividend of $0.43 per share, bringing its annual yield to 6.9%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $27 | $28 | -4% |
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (3 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.7B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.4 |
| Current P/E | 8.1 |
| YoY Growth | -3.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 47. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.32% (CS: 19) | Weak |
| RSI_14 | 47.1 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.025x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.11
- **Stop Loss:** $24.05 (4.2% risk)
- **Target:** $26.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1245
- **Position Value:** $31,261.95
- **Portfolio %:** 31.26%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*